Alle Storys
Folgen
Keine Story von november AG mehr verpassen.

november AG

EANS-News: november AG
1. quarterly report 2010

Köln, 11.5.2010 (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
3-month report
november AG - On Schedule
november AG continues upswing / publication of consolidated results
1st quarter 2010
•       reduction of liabilities 3 Mio. EUR
•       restructuring of remaining loan portfolio into predominantly long-term
        titles
•       stable liquidity
•       another significant equity increase by TEUR 2.522
•       consolidated sales revenues on schedule
•       consolidated break-even result
January 2010, the november AG succeeded in negotiating additional loan
reductions. Thereby, major shareholders waive a total of TEUR 2.197 loan
repayments. The remaining loan liabilities were restructured into long-term
deferment, long-term repayment or partial payments on the basis of a long-term
payment plan. Thus, a considerable reduction of liabilities totalling TEUR 2.956
was achieved as compared to the previous year.
At balance sheet date March 31, 2010 the november group shows a 
liquidity of TEUR 685, despite considerable loan repayments in the 
amount of TEUR 614. This is an improvement  over last year´s 
liquidity. Equity improved enormously by TEUR 2.522, primarily due to
loan waivers of major shareholders and a capital increase.
The consolidated break-even results would have been even higher by 
TEUR 100 if it were not for consultancy fees for the evaluation of 
compensation claims and analysis of company acquisitions as well as 
costs involved with the capital increase.
For further information, we refer to our 1st quarter 2010 report, 
published on our homepage: 
http://www.november.eu/company-profile/reports.html
end of announcement                               euro adhoc

Further inquiry note:

Christoph Schmitz
Leiter Finanzen, Controlling
Tel.: +49 (0) 221- 820 05 20 -10
E-Mail: info@november.de

Branche: Biotechnology
ISIN: DE000A0Z24E9
WKN: A0Z24E
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

Weitere Storys: november AG
Weitere Storys: november AG